
















































































fig. 2 Effect of tacrolinius on IL-2 gene trunscription during T cell activation S).
    Engagement of the T cell receptor initiates at least two separate signaling
    pathways driven by Ras/PKC and an elevation of intracellular Ca2'. The
    latter activates CaN. Enzymatically active CaN can dephosphorylate the
    cytoplasmic NFAT fatnily members and cause the dissociation of inhibitor
    IiCB ffom NFicliS. NFAT and NFid3 are then translocated into the nucleus
    where they can interact with their DNA binding sequences (A-E) on the IL-2
    promoter. The complex formed between FKBP- 12 and tacrolimus impedes
    access of CaN to its substrates and thereby, prevents the nuclear
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Fig. I-1Time course of changes in blood tacrolimus concentrations measured
by HPLC-MEIA. Tacrolimus was administered by 60-rnin intravenous
(A), 60-min intraportal (B) infusion or intraintestinal (C) injection at a
dose of O.3 (closed symbols) or 1.0 (open symbols) mg/kg to normal rats.













Results are mean ± S.E. of eight rats.
CL, Total clearance
V,, Volume of the central compartment
Q, Intercompartmental clearance
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Fig. I-2Time course of 6P-hydroxytestosterone formation by microsomes of rat
small intestine (A) and liver (B). Reaction mixtures containing 1 mg of
small intestine microsomes protein or O.Ol mg of liver microsomes protein
were incubated at 37eC with 2oo "iM testosterone.
Each point represents the mean ± S.E. of three independent preparations of
liver microsomes and six of small intestine microsomes.





51.0 ± 12.2 a
3.23 ± o.s4 a
O.03 18 ± O.oo52 b
O.OI05 ± O.oo20 b
5.48 ± o.13 a
Values are shown as means ± S.E. of three independent preparations of liver
microsomes, six of small intestine microsomes and three independent everted sacs.
a Values were calculated from formation rate of 63-hydroxytestosterone of 60 min.
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Fig. II-1Metabolism of tacrolimus in everted sac experiments. A: Recovery
rate oftacrolimus from the mucosal side (open columns) and tissue
(dotted columns), and calculated elimination (closed columns) with or
without miconazole. B: Metabolism of tacrolimus by everted sacs of
the duodenum, jejunum and ileum calculated from the difference in
recovery rate with and without miconazole. Each column represents
the mean ± S.E. of three rats.
*: Significantly different from duodenum, P<O.05.




















Results are means ± S.E. of eight rats.






















































































































Results are mean ± S.E. of five rats.
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Time course of changes in blood tacrolimus concentrations measured by
MEIA following intraintestinal iajection at a dose of 1.0 mgtkg.
Tacrolimus was administered to sham-operated (A),jejunum-resected (B) or
ileum-resected rats (C). Each point represents the mean ± S.E. of five rats.
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Fig. II-6A schematic diagram depicting the process of first-pass extraction in the
jejunum and ileum following an oral administration of tacrolimus. To gain
entry into the body, tacrolimus absorbed from the gut lumen into epithelial cells
(shaded arrow) is metabolized by CYP3A (closed arrow), and is also excreted
by Pgp (hatched arrow), then remnant tacrolimus diffuses into the portal blood
(open arrow). In thejejunum, the expression level of CYP3A is higher than that
in the ileum and, the expression level of Pgp is lower than that in ileum.
Therefore, the metabolic activity of tacrolimus in the jejunum is higher than that
in the ileum, but the rate of diffkision into portal blood is fast. On the other hand,
the high level of Pgp expression in the ileum limits the tacrolimus diffusion rate
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